Ion Beam Applications acquires Modus QA

IBA (Ion Beam Applications), a particle accelerator technology and dosimetry quality assurance solutions company, has acquired Modus Medical Devices (Modus QA), a Canadian company based in London, Ontario, specialising in phantoms for quality assurance for radiation therapy.

Founded in 2000 and employing about 20 people, Modus QA specialises in quality assurance for complex radiation therapy technologies, such as image-guided radiation therapy (IGRT), surface guided radiation therapy (SGRT) and respiratory gating that have led to advances in patient treatment. It specialises in phantoms, a manufactured product made to resemble human organ or tissue used to quantify the potential effects of a radiation dose on a patient. The company has a solid installed base, with over 6,500 phantoms used in more than 4,000 clinics and hospitals worldwide. 

Through this acquisition, IBA aims to benefit from synergies both in R&D and in sales and enable it to diversify its product catalogue. IBA will leverage its client base to channel Modus QA’s products and aim to expand its reach to new markets in Europe and Asia. 

Together, IBA and Modus QA will expand their product portfolio in medical imaging and in proton therapy and further strengthen existing relationships with Original Equipment Manufacturers (OEMs). Also, within proton therapy, Modus QA’s expertise will allow IBA to develop new dosimetry products, to offer an end-to-end range of quality assurance products to proton therapy centres. 

Jean-Marc Bothy, president of IBA Dosimetry, said: “Modus QA are renowned experts in the dosimetry space and this highly complementary acquisition further enhances our world leading dosimetry offering. We are very pleased to welcome the Modus QA team’s expertise to the Dosimetry team and are looking forward to working together to deliver IBA Dosimetry’s mission to treat even more patients safely.” 

Olivier Legrain, chief executive officer of IBA, added: “We welcome all Modus employees to the IBA family. This acquisition is not just important for the Dosimetry business but is reflective of our wider company strategy to seek out value-enhancing business opportunities to build out our state-of-the-art product offering across our target markets.”